Daiichinkyo CoDSKYF -4.91%73 Net Margin % is 7.20% as of Mar. 2026, which is 23% below its 10-year median of 9.30. GuruFocus rates DSKYF with a GF Score™ of 73/100 and a GF Value™ of $40.31 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 956 Drug Manufacturers companies, Daiichinkyo Co ranks better than 71.23% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Daiichinkyo Co's Net Income for the
three
months ended in Mar. 2026 was $267 Mil. Daiichinkyo Co's Revenue for the
three
months ended in Mar. 2026 was $3,716 Mil. Therefore, Daiichinkyo Co's net margin for the quarter that ended in Mar. 2026 was 7.20%.
The historical rank and industry rank for Daiichinkyo Co's Net Margin % or its related term are showing as below:
DSKYF'
s Net Margin % Range Over the Past 10 Years
Min: 5.6 Med: 9.3 Max: 15.68
Current: 12.24
DSKYF's Net Margin % is ranked better than 71.23% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs DSKYF: 12.24
Daiichinkyo Co (OTCPK:DSKYF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Daiichinkyo Co Net Margin % Related Terms
Daiichinkyo Co Net Margin % Historical Data
* Premium members only.
The historical data trend for Daiichinkyo Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiichinkyo Co (DSKYF) has a Net Margin % of 7.20% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Daiichinkyo Co and its competitors. This is 23% below median its historical median of 9.30. Over the past decade, Daiichinkyo Co's Net Margin % has ranged from 5.60 to 15.68. According to the industry distribution chart, Daiichinkyo Co ranks #275 out of 956 companies in the Drug Manufacturers industry, placing it in the top 28.8%.
Is Daiichinkyo Co's Net Margin % too high?
Daiichinkyo Co's current Net Margin % of 7.20% is 23% below median its 10-year median of 9.30. Over the past 10 years, this metric has ranged from a low of 5.60 to a high of 15.68. The Drug Manufacturers industry median Net Margin % is 5.56. Daiichinkyo Co's value of 7.20% is 29.5% above this industry median. Based on the distribution chart, Daiichinkyo Co ranks #275 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Daiichinkyo Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #275 out of 956 companies for Net Margin %. This puts Daiichinkyo Co in the upper half of its industry. The industry median Net Margin % is 5.56. Daiichinkyo Co's value of 7.20% is 29.5% above this benchmark. Historically, Daiichinkyo Co's own Net Margin % has ranged from 5.60 to 15.68 over the past decade. While the company's 10-year median is 9.30 vs. the industry median of 5.56, Daiichinkyo Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiichinkyo Co's current Net Margin % of 7.20% is 29.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Daiichinkyo Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiichinkyo Co's current Net Margin % is 7.20%, which is 23% below median its own 10-year median of 9.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (DSKYF) is currently considered Significantly Undervalued. The stock's GF Value™ is $40.31, compared to a current price of $14.76 — trading 63.4% below its estimated fair value. The current Net Margin % is 7.20%, which is 23% below median its 10-year median of 9.30 and 29.5% above the Drug Manufacturers industry median of 5.56. Daiichinkyo Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Daiichinkyo Co (DSKYF), the current Net Margin % is 7.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (DSKYF) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of $14.76 is trading 63.4% below its estimated GF Value™ of $40.31.
GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.
Key valuation signals for DSKYF:
Net Margin %: 7.20% (23% below median its 10-year median of 9.30)
GF Value™: $40.31 vs. price of $14.76 (63.4% below fair value)
Industry Position: 29.5% above the Drug Manufacturers median (#275 of 956)
No single metric tells the full story. See the DSKYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
73GF Score
Get the complete analysis for DSKYF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DSKYF has been successfully added to your 
